Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Phthalimide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B known ✓ | P49841 | 1/20 | 0.94 |
| ▸ | PARP1 known ✓ | P09874 | 4/20 | 0.56 |
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.56 |
| ▸ | MEN1 known ✓ | O00255 | 4/20 | 0.47 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.46 |
| ▸ | THRB known ✓ | P10828 | 2/20 | 0.45 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 3/20 | 0.75 |
| ▸ | CASP3 | P42574 | 2/20 | 0.75 |
| ▸ | CASP6 | P55212 | 2/20 | 0.75 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.75 |
| ▸ | CASP2 | P42575 | 1/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | FER | P16591 | 1/20 | 0.56 |
| ▸ | LTK | P29376 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalimide SCHEMBL27572997 | 1.00 | GSK3B (0.94) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL28226707 | 0.97 | GSK3B (1.00) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL7771670 | 0.97 | GSK3B (1.00) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL29366030 | 0.97 | GSK3B (1.00) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL64 | 0.97 | GSK3B (1.00) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL11040503 | 0.97 | GSK3B (1.00) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL10192661 | 0.97 | GSK3B (1.00) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL30125197 | 0.97 | GSK3B (1.00) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL28074926 | 0.94 | GSK3B (0.83) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL228977 | 0.94 | GSK3B (0.94) | GSK3BCASP7CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101550102-B | Method for preparing di-(N-methyl phthalimide) ether | UNIV NORTHWEST A&F | 2010-12-01 | — | — | CN | claimed |
| CN-101139315-B | Method for preparing di(N-methyl phthalimide) ether | SHANGHAI RES INST SYNTHETIC RESINS | 2010-04-07 | — | — | CN | claimed |
| CN-101550102-A | Preparation method of bis- (N-methyl phthalimide) ether | UNIV NORTHWEST A&F (CN) | 2009-10-07 | — | — | CN | claimed |
| CN-100460390-C | Bi(N-methylphthalic imidine) ester preparation method | SHANGHAI INST TECHNOLOGY (CN) | 2009-02-11 | — | — | CN | claimed |
| CN-101139315-A | Method for preparing di(N-methyl phthalimide) ether | SHANGHAI RES INST OF SYNTHETIC (CN) | 2008-03-12 | — | — | CN | claimed |
| CN-101007782-A | Bi(N-methylphthalic imidine) ester preparation method | SHANGHAI INST TECHNOLOGY (CN) | 2007-08-01 | — | — | CN | claimed |
| EP-0274601-A2 | Synthesis of bis (n-substituted phthalimide) ethers | GENERAL ELECTRIC COMPANY (US) | 1988-07-20 | — | — | EP | claimed |
| US-4757149-A | Synthesis of bis(N-substituted phthalimide)ethers | GENERAL ELECTRIC COMPANY (US) | 1988-07-12 | — | — | US | claimed |
| US-11866417-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220031661-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | UNIVERSITY OF KANSAS | 2022-02-03 | — | — | US | disclosed |
| WO-2020117832-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | UNIVERSITY OF KANSAS (US) | 2020-06-11 | — | — | WO | disclosed |
| CN-103539931-A | Preparation method of catalyst for synthesizing medium and low-molecular weight polyethylene oxide | SHANGHAI LIAN SHENG CHEMICAL CO LTD | 2014-01-29 | — | — | CN | disclosed |
| CN-101550102-B | Method for preparing di-(N-methyl phthalimide) ether | UNIV NORTHWEST A&F | 2010-12-01 | — | — | CN | disclosed |
| CN-101139315-B | Method for preparing di(N-methyl phthalimide) ether | SHANGHAI RES INST SYNTHETIC RESINS | 2010-04-07 | — | — | CN | disclosed |
| EP-0274601-A2 | Synthesis of bis (n-substituted phthalimide) ethers | GENERAL ELECTRIC COMPANY (US) | 1988-07-20 | — | — | EP | disclosed |
| EP-0274601-A2 | Synthesis of bis (n-substituted phthalimide) ethers | GENERAL ELECTRIC COMPANY (US) | 1988-07-20 | — | — | EP | disclosed |
| EP-0274601-A2 | Synthesis of bis (n-substituted phthalimide) ethers | GENERAL ELECTRIC COMPANY (US) | 1988-07-20 | — | — | EP | disclosed |
| US-4757149-A | Synthesis of bis(N-substituted phthalimide)ethers | GENERAL ELECTRIC COMPANY (US) | 1988-07-12 | — | — | US | disclosed |
| US-4757149-A | Synthesis of bis(N-substituted phthalimide)ethers | GENERAL ELECTRIC COMPANY (US) | 1988-07-12 | — | — | US | disclosed |
| US-4757149-A | Synthesis of bis(N-substituted phthalimide)ethers | GENERAL ELECTRIC COMPANY (US) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866417-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | QDPR, HTR3D, IAPP | GSK3B 2241/4885PARP1 2244/4885ACVR1 2830/4885 |
| US-20220031661-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | BLVRB, TFPI, ETFB | GSK3B 4352/4885PARP1 4494/4885ACVR1 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.